No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MNMD240719P8000
- 0.64
- +0.04+6.67%
15min DelayClose Jul 12 15:59 ET
0.64High0.60Low
0.60Open0.60Pre Close2 Volume204 Open Interest8.00Strike Price124.00Turnover68.34%IV1.34%PremiumJul 19, 2024Expiry Date0.54Intrinsic Value100Multiplier6DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.7619Delta0.4577Gamma11.94Leverage Ratio-0.0156Theta-0.0010Rho-9.09Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
Express News | Mind Medicine (MindMed) Inc - “at the Market Offering” Sales Agreement Prospectus Supplement Covering Offering of up to $150 Mln of Common Shares
Express News | Mind Medicine (MindMed) Inc Files for Mixed Shelf-SEC Filing
Express News | MindMed To Be Included In Russell 2000 And Russell 3000 Indexes, Effective Today
MindMed to Be Included in Russell 2000 and Russell 3000 Indexes
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced
Express News | Cantor Fitzgerald Reiterates Overweight on Mind Medicine
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of
Comments
$Mind Medicine(MNMD.US$ MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
3
$Seelos Therapeutics(SEEL.US$ $Cybin(CYBN.US$ $Mind Medicine(MNMD.US$ FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
5
13
$Mind Medicine(MNMD.US$ i swear my brokerage (not moomoo) knows what stocks i buy and instantly shorts my stock
1
2
$Mind Medicine (MNMD.US)$ all work force buisness owner operators should invest into this companies products. this could not only benifit people with the disorders outlined in their descriptions but think about our work force in general I know for the agency I work for we have call ins all the time and generally speaking it's almost always the same people it isn't just my agency but national, jobs every wherewould benifit. so this company could help everyone every where! This company will ris...
1
Read more